Novo Nordisk (NVO) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that its drug semaglutide 2.4 mg significantly improves liver fibrosis and resolves steatohepatitis in adults with MASH. These findings, indicating a safe and well-tolerated profile, could position semaglutide as a key player in treating this growing health concern. The company plans to seek regulatory approvals in the US and EU by mid-2025.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.